BCL2 and metabolic dysfunction-associated steatotic liver disease: Furthermore, a pan-caspase inhibitor or an overexpression of the anti-apoptotic Bcl2 protein was shown to reduce fibrosis in an animal model of NAFLD and fibrosis, respectively (Mitchell et al., 2009; Witek et al., 2009).